Ask AI
ProCE Banner Activity

ASCENT-03: Safety Analysis of Sacituzumab Govitecan vs Chemotherapy in Previously Untreated Patients With Advanced TNBC Ineligible for PD-(L)1 Inhibitors

Conference Coverage
Slideset

In the phase III ASCENT-03 trial, treatment with sacituzumab govitecan compared with chemotherapy in patients with previously untreated metastatic TNBC not eligible for PD-(L)1 inhibitors showed a safety profile consistent with prior experience with this therapy and manageable according to established guidelines.

Released: December 15, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Genentech, a member of the Roche Group, Gilead Sciences, Inc., Lilly, Novartis Pharmaceuticals Corporation, and Stemline Therapeutics, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group

Gilead Sciences, Inc.

Lilly

Novartis Pharmaceuticals Corporation

Stemline Therapeutics, Inc.

Target Audience

This activity is intended for oncologists and other healthcare professionals who care for patients with breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify subpopulations of patients with breast cancer most likely to benefit from a specific treatment plan based on predictive biomarkers

  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with breast cancer
  • Evaluate new data on novel agents and therapeutic approaches for patients with breast cancer